Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011;10(1-2):32-4.

Reversible therapy-related dysplastic hematopoiesis following Beta Interferon Therapy in Multiple Sclerosis Patients: Report of 2 Cases

Seyed Massood Nabavi  1 , Ali Hamzehloo, Jalaledin Shams, Damineh Morsali
Affiliations
Case Reports

Reversible therapy-related dysplastic hematopoiesis following Beta Interferon Therapy in Multiple Sclerosis Patients: Report of 2 Cases

Seyed Massood Nabavi et al. Iran J Neurol. 2011.

Abstract

Background: Interferon beta-la and -1b have been increasingly used for the treatment of multiple sclerosis (MS). The most frequent systemic adverse effects are flu-like symptoms. Laboratory abnormalities include asymptomatic leukopenia and elevated hepatic transaminases. Myelodysplastic Syndrome (MDS) refers to a spectrum of hematological disorders which can occur in different situations. Several hematological abnormalities have been reported following interferon therapy.

Methods: We report two cases of secondary MDS after long term interferon therapy by using the laboratory data and bone marrow results.

Conclusion: Both of our cases were reversible; although treatment with IFNβ-1a and-1b is safe and well tolerated in the majority of population, we should be careful about this premalignant hematological disorder.

Keywords: Beta Interferon Therapy; Dysplastic Hematopoiesis; Multiple Sclerosis.

PubMed Disclaimer

References

    1. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Advances in Neurological Disorders. 2010;3:3–13. - PubMed
    1. Klawiter EC, Cross AC, Naismith RT. The present efficacy of multiple sclerosis therapeutics. Neurology. 2009;73:984–990. - PMC - PubMed
    1. Fontoura P, Garren H. Multiple sclerosis therapies: molecular mechanisms and future. Results Probl Cell Differ. 2010;51:259–85. - PubMed
    1. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–42. - PubMed
    1. Nguyen PL. The myelodysplastic syndromes. Hematology/Oncology Clinics of North America. 2009;23:675–691. - PubMed

Publication types

LinkOut - more resources